Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging.

This report describes the precursor synthesis and the no-carrier-added (nca) radiosynthesis of the new A(1) adenosine receptor (A(1)AR) antagonist [(18)F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (CPFPX), 3, with fluorine-18 (half-life = 109.6 min). Nucleophilic radiofluorination of the precursor tosylate 8-cyclopentyl-3-(3-tosyloxypropyl)-7-pivaloyloxymethyl-1-propylxanthine, 2, with nca [(18)F]KF under aminopolyether-mediated conditions (Kryptofix 2.2.2/K(2)CO(3)) followed by deprotection was straightforward and, after formulation, gave the radioligand ready for injection with a radiochemical yield of 45 +/- 7%, a radiochemical purity of >98% and a specific radioactivity of >270 GBq/micromol (>7.2 Ci/micromol). Preparation time averaged 55 min. The synthesis proved reliable for high batch yields ( approximately 7.5 GBq) in routine production (n = 120 runs). The radiotracer was pharmacologically evaluated in vitro and in vivo and its pharmacokinetics in rodents determined in detail. After iv injection a high accumulation of radioactivity occurred in several regions of mouse brain including thalamus, striatum, cortex, and cerebellum. Antagonism by the specific A(1)AR antagonists 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) and N(6)-cyclopentyl-9-methyladenine (N-0840), but not with the A(2)AR antagonist 3,7-dimethyl-1-propargylxanthine (DMPX), indicated specific and reversible binding of the radioligand to A(1)AR in cortical and subcortical regions of interest. In mouse blood at least two polar metabolites formed rapidly (50% at 5 min after tracer application). However, chromatographic analyses of brain homogenate extracts taken 60 min pi showed that >98% of radioactivity was unchanged radioligand. Chromatographic isolation and reinjection of peripherally formed radioactive metabolites revealed no accumulation of radioactivity in mouse brain, probably due to the polarity of the metabolites. These preliminary results suggest that nca [(18)F]CPFPX is a useful radioligand for the noninvasive imaging of the brain A(1)AR.

[1]  R. Lewis,et al.  A1 adenosine receptor antagonists as ligands for positron emission tomography (PET) and single-photon emission tomography (SPET). , 1998, Journal of medicinal chemistry.

[2]  D. Henry,et al.  A SIMPLIFIED HIGH-PRESSURE LIQUID CHROMATOGRAPHY METHOD FOR DETERMINING LIPOPHILICITY FOR STRUCTURE-ACTIVITY RELATIONSHIPS , 1983 .

[3]  M. Emri,et al.  Preparation and primary evaluation of [11C]CSC as a possible tracer for mapping adenosine A2A receptors by PET. , 1999, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[4]  F. Fazio,et al.  Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography. , 2000, Journal of medicinal chemistry.

[5]  M. Kiyosawa,et al.  Carbon-11-labeled KF15372: a potential central nervous system adenosine A1 receptor ligand. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .

[7]  Martin J. Lohse,et al.  8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) — a selective high affinity antagonist radioligand for A1 adenosine receptors , 1987, Naunyn-Schmiedeberg's Archives of Pharmacology.

[8]  James A. Bristol,et al.  Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  H. Coenen,et al.  Preparation of N.C.A. [17‐18F]‐fluoroheptadecanoic acid in high yields via aminopolyether supported, nucleophilic fluorination , 1986 .

[10]  D. Brooks,et al.  Evaluation of [4‐O‐methyl‐11C]KW‐6002 as a potential PET ligand for mapping central adenosine A2A receptors in rats , 2001, Synapse.

[11]  J. Downey,et al.  Ischemic preconditioning: from basic mechanisms to clinical applications. , 2000, Pharmacology & therapeutics.

[12]  G Burnstock,et al.  Nomenclature and Classification of Purinoceptors* , 2005 .

[13]  M. Senda,et al.  11C-labeled KF18446: a potential central nervous system adenosine A2a receptor ligand. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  M. Kiyosawa,et al.  Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography. , 2000, Nuclear medicine and biology.

[15]  C. Hansch,et al.  Lipophilic character and biological activity of drugs. II. The parabolic case. , 1973, Journal of pharmaceutical sciences.

[16]  S. Rivkees,et al.  Are A3 adenosine receptors expressed in the brain? , 2000, Neuroreport.

[17]  J. Shryock,et al.  Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Mark L. Greenberg,et al.  Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. , 1985, Journal of the American College of Cardiology.

[19]  C. Müller.  A1 adenosine receptors and their ligands: overview and recent developments. , 2001, Farmaco.

[20]  K. Hamacher,et al.  Computer-aided synthesis (CAS) of no-carrier-added 2-[18F]fluoro-2-deoxy-D-glucose: an efficient automated system for the aminopolyether-supported nucleophilic fluorination , 1990 .

[21]  K. Kogure,et al.  Alteration of adenosine A1 receptor binding in the post‐ischaemic rat brain , 1994, Neuroreport.

[22]  M. Kiyosawa,et al.  Evaluation of carbon-11 labeled KF15372 and its ethyl and methyl derivatives as a potential CNS adenosine A1 receptor ligand. , 1997, Nuclear medicine and biology.

[23]  Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K+ channels in cerebral ischemic preconditioning. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Evaluation of iodinated and brominated [11C]styrylxanthine derivatives asin vivo radioligands mapping adenosine A2A receptor in the central nervous system , 2000, Annals of nuclear medicine.

[25]  T. Rall.  Drugs used in the treatment of asthma , 1990 .

[26]  J. Daly,et al.  Analogs of caffeine: antagonists with selectivity for A2 adenosine receptors. , 1986, Life sciences.

[27]  J. Fastbom,et al.  The distribution of adenosine a1 receptors and 5'-nucleotidase in the brain of some commonly used experimental animals , 1987, Neuroscience.

[28]  B B Fredholm,et al.  Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study , 1997, Synapse.

[29]  Y. Tanabe,et al.  Practical and efficient methods for sulfonylation of alcohols using Ts(Ms)Cl/Et3N and catalytic Me3H·HCl as combined base: Promising alternative to traditional pyridine , 1999 .